Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Complete Title: APEC1621K: NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Trial Phase: II

Investigator: Katherine Tarlock

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.

Keywords:

Glioma
Medulloblastoma
Neuroblastoma
Lymphoma, Non-Hodgkin (NHL)
Sarcoma
Solid Tumors
Wilms' Tumor
Neoplasms, Germ Cell and Embryonal
Ependymoma
Rhabdomyosarcoma
Sarcoma, Ewing
Osteosarcoma
Sarcoma, Soft Tissue
Rhabdoid Tumor
Histiocytosis, Langerhans-Cell
Hepatoblastoma
Neuroectodermal Tumors, Primitive, Peripheral

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.